Glucose-conjugated MGMT inhibitor - CAS 382607-78-5
Catalog number: 382607-78-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
O6BTG-C8-βGlu is a glucose-conjugated MGMT inhibitor. It could reduce the inhibitor's ability to inhibit MGMT.
Publictions citing BOC Sciences Products
  • >> More
1.Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging.
Mühlhausen U1, Schirrmacher R, Piel M, Lecher B, Briegert M, Piee-Staffa A, Kaina B, Rösch F. J Med Chem. 2006 Jan 12;49(1):263-72.
O(6)-Substituted guanine derivatives are powerful agents used for tumor cell sensitization by inhibition of the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT). To provide targeted accumulation of MGMT inhibitors in tumor tissue as well as tools for in vivo imaging, we synthesized iodinated C(8)-alkyl-linked glucose conjugates of 2-amino-6-(5-iodothenyl)-9H-purine (O(6)-(5-iodothenyl) guanine, ITG) and 2-amino-6-(3-iodobenzyloxy)-9H-purine (O(6)-(5-iodobenzyl) guanine, IBG). These compounds have MGMT inhibitor constants (IC(50) values) of 0.8 and 0.45 microM for ITGG and IBGG, respectively, as determined in HeLa S3 cells after 2-h incubation with inhibitor. To substantiate that the (131)I-(hetero)arylmethylene group at the O(6)-position of guanine is transferred to MGMT, both the glucose conjugated inhibitors ITGG and IBGG and the corresponding nonglucose conjugated compounds ITG and IBG were labeled with iodine-131. The radioiodinations of all compounds with [(131)I]I(-) were performed with radiochemical yields of >70% for the destannylation of the corresponding tri-n-butylstannylated precursors.
2.Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors.
Reinhard J1, Eichhorn U, Wiessler M, Kaina B. Int J Cancer. 2001 Aug 1;93(3):373-9.
The DNA-repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is a decisive determinant of resistance of tumor cells to methylating and chloroethylating anti-cancer drugs. Therefore, selective inhibition of MGMT in tumors is expected to cause tumor sensitization. Several inhibitors of MGMT have been developed which function in both tumors and normal tissue. To deplete MGMT preferentially in tumors, strategies to target the inhibitor to the tumor tissue need to be developed. Here, we report on the properties of glucose-conjugated MGMT inhibitors that might be useful for tumor targeting since tumor cells frequently over-express glucose transporter. O(6)-Benzylguanine (O6BG), 8-aza-O(6)-benzylguanine, O(6)-(4-bromothenyl)-guanine (O6BTG) and the corresponding spacer-linked beta-D-glucose conjugates were analyzed comparatively for MGMT-inhibitory activity. Substitution at the N9 position of the purine moiety resulted generally in a reduction in the efficiency with which the inhibitors blocked MGMT.
3.Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.
Kaina B1, Mühlhausen U, Piee-Staffa A, Christmann M, Garcia Boy R, Rösch F, Schirrmacher R. J Pharmacol Exp Ther. 2004 Nov;311(2):585-93. Epub 2004 Jul 13.
The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is an important suicide enzyme involved in the defense against O(6)-alkylating mutagens. It also plays a role in the resistance of tumors to anticancer drugs targeting the O(6)-position of guanine, such as temozolomide and fotemustine. Several potent MGMT inhibitors have been developed sensitizing cells to O(6)-alkylating agents. Aimed at targeting MGMT inhibitors to tumor cells, we synthesized MGMT inhibitory compounds conjugated with glucose to improve uptake in tumor cells. Here, we compared O(6)-benzylguanine, O(6)-2-fluoropyridinylmethylguanine (O(6)FPG), O(6)-3-iodobenzylguanine, O(6)-4-bromothenylguanine, and O(6)-5-iodothenylguanine with the corresponding C8-linker beta-d-glucose derivatives. All glucose conjugated inhibitors were 3- to 5-fold less effective than the corresponding nonconjugated drugs as to MGMT inhibition that was measured in cell extracts (in vitro) and cultivated HeLaS3 cells (in vivo).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related DNMT Products

CAS 3690-10-6 Zebularine

(CAS: 3690-10-6)

Zebularine is a nucleoside analog of cytidine. It is a "transition state analog inhibitor of cytidine deaminase by binding to the active size as covalent hydrat...

CAS 192441-08-0 Lomeguatrib

(CAS: 192441-08-0)

Lomeguatrib, also known as PaTrin-2,  is a potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase. Lomeguatrib is also a nontoxic low-molecular weight pseudos...

CAS 1020149-73-8 SGI-1027

(CAS: 1020149-73-8)

SGI-1027 is a potent DNMT inhibitor, which reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Treatme...

(CAS: 890643-16-0)

DC-05 is a potent and selective non-nucleoside DNMT1 (DNA methyltransferase 1) inhibitor with IC50 of 10.3 uM. It has significant selectivity toward other AdoMe...

CAS 48208-26-0 RG108

(CAS: 48208-26-0)

RG108 is an inhibitor of DNA methyltransferase with IC50 of 115 nM, does not cause trapping of covalent enzymes.

(CAS: 500017-70-9)

DC_517 is a novel selective non-nucleoside inhibitor of DNMT1. (IC50 = 1.7 μM), was found to be more potent than DC_05.

CAS 382607-78-5 Glucose-conjugated MGMT inhibitor

Glucose-conjugated MGMT inhibitor
(CAS: 382607-78-5)

O6BTG-C8-βGlu is a glucose-conjugated MGMT inhibitor. It could reduce the inhibitor's ability to inhibit MGMT.

CAS 2353-33-5 Decitabine

(CAS: 2353-33-5)

Decitabine is a potent inhibitor of DNA methylation, used to treat myelodysplastic syndrome (MDS).

Chemical Structure

CAS 382607-78-5 Glucose-conjugated MGMT inhibitor

Quick Inquiry

Verification code

Featured Items